Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OS Therapies IncOSTX · Entity 6950 | Director | December 31, 2024 | February 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OS Therapies Inc
Report date December 31, 2024 · Filed February 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-qualified stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 | Direct | 400,000 |
Reported balance
After 2024-12-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-12-05 · Grant · Acquired 400,000 · Balance 400,000 F2: On December 5, 2024, the reporting person was granted non-qualified stock options to purchase 400,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and subject to certain vesting conditions. |
| Common StockSEC Table I · non-derivative | IndirectStateside Developments USA LLC | 198,929 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 198,929 F1: Colin Goddard serves as the managing member of Stateside Developments USA LLC and holds sole voting and investment power with respect to these shares. |
| Common StockSEC Table I · non-derivative | Direct | 26,250 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 26,250 |
Filing footnotes · ownership attribution and instrument terms
F1: Colin Goddard serves as the managing member of Stateside Developments USA LLC and holds sole voting and investment power with respect to these shares.
F2: On December 5, 2024, the reporting person was granted non-qualified stock options to purchase 400,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and subject to certain vesting conditions.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ENDOCYTE INC
Report date December 21, 2018 · Filed December 21, 2018
Section 16 reporting ended · disclosed 2018-12-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2018-12-21 · Disposition to issuer · Disposed 7,800 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2018-12-21 · Disposition to issuer · Disposed 3,300 · Balance 0 F2: This restricted stock unit ("RSU") award provided for vesting and settlement 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.37 · Expires 2023-11-07 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-12-21 · Disposition to issuer · Disposed 28,000 · Balance 0 F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.69 · Expires 2024-05-15 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-12-21 · Disposition to issuer · Disposed 14,000 · Balance 0 F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.02 · Expires 2025-05-14 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-12-21 · Disposition to issuer · Disposed 13,500 · Balance 0 F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2026-05-05 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-12-21 · Disposition to issuer · Disposed 13,500 · Balance 0 F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.27 · Expires 2027-05-04 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-12-21 · Disposition to issuer · Disposed 19,500 · Balance 0 F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.81 · Expires 2028-05-03 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-12-21 · Disposition to issuer · Disposed 19,500 · Balance 0 F4: This Company stock option was scheduled to vest 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes.
F2: This restricted stock unit ("RSU") award provided for vesting and settlement 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
F4: This Company stock option was scheduled to vest 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 05, 2024 Filed Feb 14, 2025 16:23 UTC | OS Therapies Inc OSTX · Entity 6950 | GrantNon-qualified stock options (right to buy) · Derivative | 400,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0000921895-25-000493 · form513679001god_02142025.xml · derivative · entry 3 GODDARD COLIN · CIK 0001225199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common stock, par value $0.001 per share · 400,000 shares Expires not disclosed F2 · derivative.exercise_date: On December 5, 2024, the reporting person was granted non-qualified stock options to purchase 400,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and subject to certain vesting conditions. F2 · derivative.expiration_date: On December 5, 2024, the reporting person was granted non-qualified stock options to purchase 400,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and subject to certain vesting conditions. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 12:49 UTC | ENDOCYTE INC ECYT · Entity 161591 | Disposition to issuerStock Option (right to buy) · Derivative | 19,500 | $13.19 Strike: $10.81 | $257,205.00 |
DisclosureSEC source: 0001104659-18-074344 · a4.xml · derivative · entry 8 GODDARD COLIN · CIK 0001225199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,500 shares Expires 2028-05-03 F4 · price: This Company stock option was scheduled to vest 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F4 · derivative.exercise_date: This Company stock option was scheduled to vest 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 12:49 UTC | ENDOCYTE INC ECYT · Entity 161591 | Disposition to issuerStock Option (right to buy) · Derivative | 19,500 | $21.73 Strike: $2.27 | $423,735.00 |
DisclosureSEC source: 0001104659-18-074344 · a4.xml · derivative · entry 7 GODDARD COLIN · CIK 0001225199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,500 shares Expires 2027-05-04 F3 · price: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F3 · derivative.exercise_date: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 12:49 UTC | ENDOCYTE INC ECYT · Entity 161591 | Disposition to issuerStock Option (right to buy) · Derivative | 13,500 | $20.65 Strike: $3.35 | $278,775.00 |
DisclosureSEC source: 0001104659-18-074344 · a4.xml · derivative · entry 6 GODDARD COLIN · CIK 0001225199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,500 shares Expires 2026-05-05 F3 · price: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F3 · derivative.exercise_date: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 12:49 UTC | ENDOCYTE INC ECYT · Entity 161591 | Disposition to issuerStock Option (right to buy) · Derivative | 13,500 | $17.98 Strike: $6.02 | $242,730.00 |
DisclosureSEC source: 0001104659-18-074344 · a4.xml · derivative · entry 5 GODDARD COLIN · CIK 0001225199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,500 shares Expires 2025-05-14 F3 · price: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F3 · derivative.exercise_date: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 12:49 UTC | ENDOCYTE INC ECYT · Entity 161591 | Disposition to issuerStock Option (right to buy) · Derivative | 14,000 | $17.31 Strike: $6.69 | $242,340.00 |
DisclosureSEC source: 0001104659-18-074344 · a4.xml · derivative · entry 4 GODDARD COLIN · CIK 0001225199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires 2024-05-15 F3 · price: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F3 · derivative.exercise_date: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 12:49 UTC | ENDOCYTE INC ECYT · Entity 161591 | Disposition to issuerStock Option (right to buy) · Derivative | 28,000 | $13.63 Strike: $10.37 | $381,640.00 |
DisclosureSEC source: 0001104659-18-074344 · a4.xml · derivative · entry 3 GODDARD COLIN · CIK 0001225199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,000 shares Expires 2023-11-07 F3 · price: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F3 · derivative.exercise_date: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 12:49 UTC | ENDOCYTE INC ECYT · Entity 161591 | Disposition to issuerCommon Stock | 3,300 | $24.00 | $79,200.00 |
DisclosureSEC source: 0001104659-18-074344 · a4.xml · nonDerivative · entry 2 GODDARD COLIN · CIK 0001225199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: This restricted stock unit ("RSU") award provided for vesting and settlement 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 12:49 UTC | ENDOCYTE INC ECYT · Entity 161591 | Disposition to issuerCommon Stock | 7,800 | $24.00 | $187,200.00 |
DisclosureSEC source: 0001104659-18-074344 · a4.xml · nonDerivative · entry 1 GODDARD COLIN · CIK 0001225199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes. Read SEC document |
| May 03, 2018 Filed May 4, 2018 17:07 UTC | ENDOCYTE INC ECYT · Entity 161591 | GrantStock Option (right to buy) · Derivative | 19,500 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001179110-18-006321 · edgar.xml · derivative · entry 2 GODDARD COLIN · CIK 0001225199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2028-05-03 F2 · derivative.exercise_date: 100% of options vest on the business day prior to the next annual stockholder meeting following the date of grant. Read SEC document |
| May 03, 2018 Filed May 4, 2018 17:07 UTC | ENDOCYTE INC ECYT · Entity 161591 | GrantCommon Stock | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006321 · edgar.xml · nonDerivative · entry 1 GODDARD COLIN · CIK 0001225199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,100 F1 · shares: Represents restricted stock units that will vest 100% on the business day prior to the next annual stockholder meeting following the date of grant, and will be paid in the form of one share of common stock for each restricted stock unit. Read SEC document |
| May 04, 2017 Filed May 5, 2017 17:06 UTC | ENDOCYTE INC ECYT · Entity 161591 | GrantStock Option (right to buy) · Derivative | 19,500 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001179110-17-006710 · edgar.xml · derivative · entry 2 GODDARD COLIN · CIK 0001225199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2027-05-04 F2 · derivative.exercise_date: 100% of options vest on the business day prior to the next annual stockholder meeting following the date of grant. Read SEC document |
| May 04, 2017 Filed May 5, 2017 17:06 UTC | ENDOCYTE INC ECYT · Entity 161591 | GrantCommon Stock | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-006710 · edgar.xml · nonDerivative · entry 1 GODDARD COLIN · CIK 0001225199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 F1 · shares: Represents restricted stock units that will vest 100% on the business day prior to the next annual stockholder meeting following the date of grant, and will be paid in the form of one share of common stock for each restricted stock unit. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.